Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21776362 | 0.81 | L3MBTL1 (0.48) | CA12CA1CA2CA9KDM6B | |
| SCHEMBL5591576 | 0.74 | — | — | |
| SCHEMBL12432398 | 0.73 | KDM6B (0.58) | CA12CA1CA2CA9KDM6B | |
| SCHEMBL353804 | 0.73 | KDM6B (0.68) | CA12CA1CA2CA9KDM6B | |
| SCHEMBL19755641 | 0.73 | FPR2 (0.50) | CA12CA1CA2CA9KDM6B | |
| SCHEMBL1781507 | 0.70 | CA12 (1.00) | CA12CA1CA2CA9KDM6B | |
| SCHEMBL888663 | 0.69 | CYP1A2 (0.33) | — | |
| SCHEMBL2651357 | 0.69 | — | — | |
| SCHEMBL17034776 | 0.67 | FPR2 (0.48) | CA12CA1CA2CA9KDM6B | |
| SCHEMBL20143838 | 0.67 | L3MBTL1 (0.48) | CA12CA1CA2CA9KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | NOVO NORDISK A/S (DK) | 2023-10-17 | — | — | US | disclosed |
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | SAINT LOUIS UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2023-06-15 | — | — | US | disclosed |
| US-20170204087-A1 | 2-OXINDOLE COMPOUNDS | CHEMOCENTRYX, INC. | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708346-B2 | Treatment and prevention of neuropathic pain with P2Y14 antagonists | P2RY14, P2RY4, P2RY13 | CA12 4122/4885CA1 3403/4885CA2 1315/4885 |
| US-20230183179-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | FABP4, FABP1, FABP3 | CA12 4539/4885CA1 4794/4885CA2 3678/4885 |
| US-20170204087-A1 | 2-OXINDOLE COMPOUNDS | CCR9, CCR1, CCRL2 | CA12 1844/4885CA1 2765/4885CA2 2992/4885 |
| US-11787837-B2 | DCHBS-active esters of PEG compounds and their use | HBB, IAPP, GLP1R | CA12 2374/4885CA1 3636/4885CA2 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.